Clinical Trial Update: SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating SX-682 in combination with pembrolizumab for metastatic or recurrent stage IIIC or IV non-small cell lung cancer; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• SX-682

Snippet

Sponsor: University of Washington | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Status: RECRUITING